1 NAME OF THE MEDICINE
Nifedipine

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ADEFIN (nifedipine) 10 or 20 is a calcium ion influx inhibitor (Calcium channel blocker or calcium antagonist).

ADEFIN tablets contain micronised nifedipine 10 mg or 20 mg as the active ingredient.

Excipients with known effect: ADEFIN tablets contain trace quantities of lactose and sulfites.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM
ADEFIN 10 : Pink-grey biconvex lacquered tablets, one side marked “A 10”, the reverse side is blank, each containing 10 mg nifedipine.

ADEFIN 20 : Pink-grey lacquered tablets, one side marked “1 U”, the reverse side with the Bayer cross; 6mm diameter each containing 20 mg nifedipine.

4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
ADEFIN 10 and 20 are indicated for:

1. the management of chronic stable angina pectoris and vasospastic angina pectoris (Prinzmetal’s angina, variant angina) due to coronary heart disease

2. the treatment of hypertension.

4.2 DOSE AND METHOD OF ADMINISTRATION
Dosage should be individualised depending on severity of disease, patient's tolerance and responsiveness to ADEFIN (nifedipine) 10 or 20 and to concurrent antihypertensive medications (see Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

Depending on the clinical picture in each case, the basic dose must be introduced gradually.
The recommended initial dose is 10 to 20 mg twice daily swallowed with a little fluid, with or without food. The tablets must not be chewed or broken up. Grapefruit juice is to be avoided. The usual adult dose is 20 mg twice daily. If required, the dose may be increased up to 40 mg twice daily. The maximum daily dose of 80 mg should not be exceeded. The recommended dose interval is about 12 hours.
Due to its pronounced anti-ischaemic and antihypertensive action, ADEFIN should be discontinued gradually, particularly when high doses are used.

ADEFIN 10 tablets permit dosage titration. Dose titration is particularly recommended for patients with severe cerebrovascular disease or patients of low body weight, on multiple therapies with other antihypertensive medicines, or for whom adverse reactions would occur at the higher initial dose. These patients are likely to have an excessive reaction to nifedipine. In addition, a finer dose adjustment is desirable in patients who experience side effects in response to the nifedipine treatment and should be individually stabilised with ADEFIN 10 tablets. Patients with hepatic dysfunction should commence therapy at 10 mg twice daily with careful monitoring.

Co-administration with CYP3A4 inhibitors or inducers may require nifedipine dose adjustment or for nifedipine not to be used at all (see Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

### 4.3 CONTRAINDICATIONS

- Known hypersensitivity to nifedipine or any of the excipients.
- Pregnancy and during lactation.
- Cardiovascular shock.
- Within the first 8 days after an acute episode of myocardial infarction.
- Concomitant administration with rifampicin (see Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

### 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

**Excessive Hypotension**

Nifedipine may be used in combination with beta-blocking medicines and other antihypertensive agents, but the possibility of potentiation of existing antihypertensive therapy should be noted. Care must also be exercised in patients with very low blood pressure (severe hypotension with systolic pressure less than 90 mmHg), in cases of manifest heart failure and in the case of severe aortic stenosis.

**Increased Angina**

As with other vasoactive substances, angina pectoris attacks may very rarely occur at the start of the treatment with nifedipine. The occurrence of myocardial infarction has been described in isolated cases, although it was not possible to distinguish this from the natural course of the underlying disease.

**Beta-Blocker Withdrawal**

When nifedipine is administered simultaneously with beta-blockers the patient should be carefully monitored, since deterioration of heart failure may develop in isolated cases.

Nifedipine has no inherent anti-arrhythmic action and therefore gives no protection against any arrhythmias which may result from abrupt withdrawal of beta-blockers. Any such withdrawal of beta-blockers should be gradual over a period of several days.

**Congestive Heart Failure**

The onset of cardiac insufficiency has occasionally been observed during clinical use. Care should be observed with patients whose cardiac reserve is poor, or who are receiving large doses of beta-blockers.
**Outflow Obstruction**

Nifedipine should be used with caution in the presence of fixed left ventricular outflow obstruction.

**Peripheral Oedema**

Mild to moderate peripheral oedema typically associated with arterial vasodilatation and not due to left ventricular dysfunction, occurs in one in ten patients treated with nifedipine. This oedema occurs primarily in the lower extremities and usually responds to diuretic therapy.

**Use in Diabetes**

A possible interference with glucose-induced insulin release should be taken into account when treating diabetic patients with nifedipine but based on extensive experience it is probably more accurate to conclude that nifedipine has no true diabetogenic potential.

**Other**

Adefin contains lactose monohydrate, patients with a rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Adefin.

**Other Nifedipine Formulations**

ADEFIN XL modified release tablets are not bioequivalent to immediate release nifedipine capsules and tablets and patients should be carefully monitored if it is decided to switch between immediate release and modified release nifedipine or vice versa.

**Use in Hepatic Impairment**

ADEFIN 10 and 20 should be used with caution in patients with mild, moderate or severe impaired liver function (see Section 5: PHARMACOLOGICAL PROPERTIES). A dose reduction may be required (see Section 4.3 DOSE AND METHOD OF ADMINISTRATION). Close monitoring of response and metabolic effect should apply. The pharmacokinetics of nifedipine has not been investigated in patients with severe hepatic impairment. Therefore, nifedipine should be used with caution in patients with severe hepatic impairment.

**Use in the Elderly**

The pharmacokinetics of nifedipine are altered in the elderly so that lower maintenance doses of nifedipine may be required compared to younger patients.

**Paediatric Use**

The safety and efficacy of nifedipine in children below 18 years has not been established.

**Effects on Laboratory Tests**

Rare, usually transient, but occasionally significant elevations of enzymes such as alkaline phosphatase, CPK, LDH, AST (SGOT) and ALT (SGPT) have been noted. The relationship to nifedipine therapy is uncertain in most cases, but probable in some. These laboratory abnormalities have rarely been associated with clinical symptoms; however, cholestasis with or without jaundice has been reported. Rare instances of allergic hepatitis have been reported.

Nifedipine like other calcium channel blockers, decreases platelet aggregation *in vitro*. Limited clinical studies have demonstrated a moderate but statistically significant decrease in platelet aggregation and increase in bleeding time in nifedipine treated patients. This is thought to be a function of inhibition of calcium transport across the platelet membrane. No clinical significance for these findings has been demonstrated.
4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Nifedipine is metabolised via cytochrome P450 3A4 (CYP3A4), located in the intestinal mucosa and the liver. Medicines that are known to inhibit or induce CYP3A4 may therefore alter the first pass or the clearance of nifedipine.

Drugs, which are inhibitors of CYP3A4 and therefore may lead to increased plasma concentrations of nifedipine, such as:

- macrolide antibiotics (e.g. erythromycin)
- anti-HIV protease inhibitors (e.g. ritonavir)
- azole antimycotics (e.g. ketoconazole)
- the antidepressants nefazodone and fluoxetine
- quinupristin/dalfopristin
- valproic acid
- cimetidine

Upon co-administration with these drugs, the blood pressure should be monitored and, if necessary, a reduction of the nifedipine dose should be considered.

Drugs that affect nifedipine

Nifedipine is metabolised via cytochrome P450 3A4 (CYP3A4), located in the intestinal mucosa and the liver. Medicines that are known to inhibit or induce CYP3A4 may therefore alter the first pass or the clearance of nifedipine.

The extent as well as the duration of interactions should be taken into account when administering nifedipine together with the following drugs:

**Rifampicin**

Rifampicin strongly induces CYP3A4. Upon co-administration with rifampicin, the bioavailability of nifedipine is distinctly reduced and thus its efficacy is weakened. The use of rifampicin in combination with nifedipine is contraindicated.

Upon co-administration of the following weak to moderate inhibitors of CYP3A4 the blood pressure should be monitored and, if necessary, a reduction in the nifedipine dose considered (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

**Macrolide antibiotics (e.g. erythromycin)**

No interaction studies have been carried out between nifedipine and macrolide antibiotics. Certain macrolide antibiotics are known to inhibit CYP3A4 mediated metabolism of other medicines, and could increase plasma concentrations of nifedipine if administered concomitantly.

Azithromycin, although structurally related to the class of macrolide antibiotics does not inhibit CYP3A4.

**Anti-HIV Protease Inhibitors**

A clinical study investigating the potential interaction between nifedipine and certain anti-HIV protease inhibitors has not yet been performed. Medicines of this class are known to inhibit CYP3A4. In addition, drugs of this class have been shown to inhibit *in vitro* the CYP3A4 mediated metabolism of nifedipine. When administered together with nifedipine, a substantial increase in plasma concentrations of nifedipine due to a decreased first-pass metabolism and decreased elimination cannot be excluded.
Azole anti-mycotics (e.g. ketoconazole)

A formal interaction study investigating the potential of a drug interaction between nifedipine and these medicines has not yet been performed. These medicines are known to inhibit CYP3A4. When administered orally with nifedipine, a substantial increase in systemic bioavailability of nifedipine due to a decreased first pass metabolism cannot be excluded.

Fluoxetine

A clinical study investigating the potential of a drug interaction between nifedipine and fluoxetine has not yet been performed. Fluoxetine has been shown to inhibit in vitro the CYP3A4 mediated metabolism of nifedipine. Therefore, an increase of nifedipine plasma concentrations upon co-administration of both medicines cannot be excluded (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

Nefazodone

A clinical study investigating the potential of a drug interaction between nifedipine and nefazodone has not yet been performed. Nefazodone is known to inhibit CYP3A4 mediated metabolism of other medicines. Therefore, an increase of nifedipine plasma concentrations upon co-administration of both medicines cannot be excluded.

Quinupristin/Dalfopristin

Simultaneous administration of quinupristin/dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine, with the effect varying markedly between individuals.

Valproic acid

No formal studies have been performed to investigate the interaction of nifedipine with valproic acid, but it has been shown to increase the plasma concentrations of another dihydropyridine calcium channel blocker (nimodipine) through enzyme inhibition. Therefore, an increase in the plasma concentrations of nifedipine is possible which may mean that an adjustment in the dosage of nifedipine may be required.

Cimetidine

Elevation of plasma nifedipine levels during cimetidine administration has been reported. It is suggested that patients taking both nifedipine and cimetidine should be carefully monitored. In case of hypotension, the dosage of nifedipine should be reduced or the patient should be treated with ranitidine, as the interaction with this medicine and nifedipine is less pronounced.

Diltiazem

Diltiazem decreases the clearance of nifedipine and, hence, increases plasma nifedipine levels. Therefore, caution should be exercised when the two medicines are used concomitantly and a reduction in the dose of nifedipine may be necessary.

Further studies

Cisapride

Simultaneous administration of cisapride and nifedipine may lead to increased plasma concentrations of nifedipine.

CYP3A4-inducing anti-epileptic drugs such as phenytoin, carbamazepine and phenobarbital (phenobarbitone)

Phenytoin induces CYP3A4. Co-administration of phenytoin with nifedipine reduces the bioavailability of nifedipine. When both medicines are concomitantly administered, the clinical response to nifedipine should be monitored and an increase in the nifedipine dose considered, if necessary. If the dose of nifedipine is increased during co-administration of both medicines, a reduction of the nifedipine dose should be considered when phenytoin is discontinued. No formal studies have been performed to
investigate the potential interaction between nifedipine and carbamazepine or phenobarbital (phenobarbitone). As both drugs have been shown to reduce the plasma concentrations of the structurally similar calcium channel blocker, nimodipine, through enzyme induction, a decrease in nifedipine plasma concentrations and hence a decrease in efficacy cannot be excluded.

**Effects of nifedipine on other drugs**

**Blood pressure lowering drugs**

Nifedipine may increase the blood pressure lowering effect of concomitant applied antihypertensives, such as:

- diuretics
- β-blockers
- ACE-inhibitors
- angiotensin I (ATI) receptor – antagonists
- other calcium antagonists
- α-adrenergic blocking agents
- PDE5 inhibitors
- α -methyldopa

When nifedipine is administered simultaneously with β-receptor blockers, patients should be carefully monitored since fairly severe hypotension can occur, deterioration of heart failure is also known to develop in isolated cases.

**Digoxin**

Simultaneous administration of nifedipine and digoxin can lead to reduced digoxin clearance and hence an increase in the plasma digoxin level. The patient should therefore be checked for symptoms of digoxin overdose as a precaution and if necessary, the glycoside dose should be reduced taking account of the plasma digoxin concentration.

**Quinidine**

When nifedipine and quinidine have been administered simultaneously, lowered quinidine levels or, after discontinuation of nifedipine, a distinct increase in the plasma quinidine level have been observed in individual cases. For this reason, when nifedipine is either additionally administered or discontinued, monitoring of the quinidine concentration and, if necessary, adjustment of the dose is recommended. Some authors reported increased plasma levels of nifedipine upon co-administration of both medicines, while others did not observe an alteration in the pharmacokinetics of nifedipine. Therefore, if quinidine is added to existing nifedipine therapy, blood pressure should be monitored, and if necessary the dose of nifedipine should be reduced.

**Tacrolimus**

Tacrolimus is metabolised by CYP3A4. Published data indicate that the dose of nifedipine administered simultaneously with tacrolimus may be reduced in individual cases. Upon co- administration of both medicines, the tacrolimus plasma concentrations should be monitored and, if necessary, a reduction in the tacrolimus dose should be considered.

**Coumarin Anticoagulants**

There have been rare reports of increased prothrombin time when nifedipine was administered to patients taking coumarin anticoagulants. However, the relationship to nifedipine therapy is uncertain.
Interactions shown not to exist

In drug interaction studies, aspirin, omeprazole, pantoprazole, ranitidine and cerivastatin did not have clinically significant effects on the pharmacokinetics of nifedipine. Nifedipine did not have clinically significant effects on the pharmacokinetics of cerivastatin, or on the effect of 100 mg aspirin on platelet aggregation and bleeding time.

Candesartan cilexetil, Irbesartan, Doxazosin

The blood pressure lowering effect of these agents may be potentiated by co-administration with nifedipine, so caution should be used in initiating combination therapy. Concomitant administration of irbesartan or doxazosin and nifedipine has no effect on the pharmacokinetics of nifedipine, and concomitant administration of candesartan cilexetil and nifedipine has no effect on the pharmacokinetics of either medicine.

Drug-food interactions

Concomitant intake of grapefruit juice inhibits the oxidative metabolism of nifedipine resulting in increased plasma concentration which may cause an increased blood pressure lowering effect. After regular intake of grapefruit juice this effect may last for at least 3 days after the last ingestion of grapefruit juice.

Ingestion of grapefruit/grapefruit juice is therefore to be avoided while taking nifedipine.

Others

Case reports of increased plasma theophylline concentrations due to nifedipine administration have been reported. Nifedipine has also been reported to have a potentiating effect on terbutaline and salbutamol induced bronchodilation in asthmatics.

Other forms of interactions

Nifedipine may cause falsely increased spectrophotometric values of urinary vanillylmandelic acid. However, measurement with HPLC is unaffected.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility

In single cases of in vitro fertilisation calcium antagonists like nifedipine have been associated with reversible biochemical changes in the spermatozoa’s head section that may result in impaired sperm function. In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilisation, and where no other explanation can be found, calcium antagonists like nifedipine should be considered as possible causes.

Use in Pregnancy

Pregnancy category: C

Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

Nifedipine carries the potential for foetal hypoxia, caesarean deliveries, prematurity and intrauterine growth retardation, which may be associated with maternal hypotension. Accordingly, it is contraindicated throughout pregnancy.

Nifedipine has been shown to produce teratogenic findings in rats, mice and rabbits, including digital anomalies, malformation of the extremities, cleft palates, cleft sternum and malformation of the ribs. Digital anomalies are possibly a result of compromised uterine blood flow. Nifedipine administration
was associated with a variety of embryotoxic, placentotoxic and foetotoxic effects, including stunted foetuses (rats, mice, rabbits), small placentas and underdeveloped chorionic villi (monkeys), embryonic and foetal deaths (rats, mice, rabbits) and prolonged pregnancy/decreased neonatal survival (rats; not evaluated in other species). All of the doses associated with the teratogenic, embryotoxic or foetotoxic effects in animals were maternally toxic and several times the recommended maximum dose for humans. There are no adequate and well controlled studies in pregnant women.

**Use in Lactation**

Nifedipine passes into breast milk. Insufficient evidence is available to determine whether effects of nifedipine occur in infants. Breastfeeding should first be stopped if nifedipine treatment becomes necessary during the breastfeeding period.

**4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

Reactions to drug, which vary in intensity from individual to individual, can impair the ability to drive or to operate machinery. This applies particularly at the start of the treatment, on changing the medication and in combination with alcohol.

**4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)**

Adverse Drug Reactions (ADRs) listed under “common” were observed with a frequency below 3 % with the exception of oedema (9.9 %) and headache (3.9 %). ADR is defined as a response to a medicinal product which is noxious and unintended and which occurs at doses normally used in man. Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility. Adverse drug reactions (ADRs) based on placebo-controlled studies with nifedipine sorted by CIOMS III categories of frequency (clinical trial database: nifedipine n = 6,486; placebo n = 5,326) are listed below. The frequencies are defined as:

- **Common** ≥ 1/100 to < 1/10
- **Uncommon** ≥ 1/1000 to < 1/100
- **Rare** ≥ 1/10000 to < 1/1000

**Table 1. ADRs reported based on clinical trial data**

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
<td>Allergic reaction</td>
<td>Purpura</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Allergic oedema/angioedema (including larynx oedema*)</td>
<td>Urticaria</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
<td>Anxiety reactions</td>
<td>Sleep disorders</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td>Paraesthesia</td>
<td>Hypaesthesia</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Somnolence</td>
<td>Dysaesthesia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tremor</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vertigo</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Migraine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypaesthesia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dysaesthesia</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td>Visual disturbances</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Palpitation</td>
<td>Chest pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Angina pectoris</td>
<td></td>
</tr>
</tbody>
</table>
### Adefin 10 and Adefin 20 – PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Vascular disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oedema</td>
<td>Syncope</td>
</tr>
<tr>
<td>Vasodilatation</td>
<td>Hypotension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Respiratory, thoracic and mediastinal disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyspnoea</td>
<td>Syncope</td>
</tr>
<tr>
<td>Nosebleed</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gastrointestinal disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>Syncope</td>
</tr>
<tr>
<td>Constipation</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Gastrointestinal and Abdominal pain</td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>Flatulence</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hepatobiliary disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase in transaminases</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Skin and subcutaneous tissue disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pruritis</td>
<td>Syncope</td>
</tr>
<tr>
<td>Rash</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Sweating</td>
<td></td>
</tr>
<tr>
<td>Erythema</td>
<td></td>
</tr>
<tr>
<td>Skin disorder</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Musculoskeletal and connective tissue disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthralgia</td>
<td>Syncope</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Muscle cramps</td>
<td></td>
</tr>
<tr>
<td>Joint swelling</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Renal and urinary disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nocturia</td>
<td>Syncope</td>
</tr>
<tr>
<td>Polyuria</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Dysuria</td>
<td></td>
</tr>
<tr>
<td>Urinary frequency increased</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>General disorders and administration site conditions</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feeling unwell</td>
<td>Syncope</td>
</tr>
<tr>
<td>Asthenia</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Unspecific pain</td>
<td></td>
</tr>
<tr>
<td>Chills</td>
<td></td>
</tr>
<tr>
<td>Abdomen enlarged</td>
<td></td>
</tr>
<tr>
<td>Photosensitivity reaction</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reproductive system and breast disorders</th>
<th>Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erectile dysfunction</td>
<td>Syncope</td>
</tr>
</tbody>
</table>

* may result in life-threatening outcome.

### Serious or Life Threatening Reactions

Anaphylactic reactions have occurred with other formulations of nifedipine.

In dialysis patients with malignant hypertension and hypovolaemia, a distinct fall in blood pressure can occur as a result of vasodilation.

The medicine has, like other members of its class, negative inotropic effects on isolated myocardial tissue. Such effects have not been seen in studies in intact animals or in man. Nevertheless, it may theoretically precipitate cardiac failure. Aggravation of cardiac insufficiency has occasionally been reported in patients with compromised cardiac function or when nifedipine is given in combination with beta-blockers.
Acute pulmonary oedema precipitated by nifedipine in a patient with fixed outflow obstruction has been reported. Care should therefore be taken with patients whose cardiac reserve is poor.

**Post marketing experience**

A small number of events identified during ongoing post-marketing surveillance associated with nifedipine for which a frequency could not be estimated are listed in the table below.

<table>
<thead>
<tr>
<th>System Organ Class (MedDRA)</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Agranulocytosis</td>
</tr>
<tr>
<td></td>
<td>Leukopenia</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Anaphylactic/anaphylactoid reactions</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Hyperglycaemia</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Hypo aesthesia</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Eye pain</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Chest pain (angina pectoris)</td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td>Dyspnoea</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Vomiting</td>
</tr>
<tr>
<td></td>
<td>Gastro-oesophageal sphincter insufficiency</td>
</tr>
<tr>
<td></td>
<td>Gum hyperplasia</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Jaundice</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Toxic Epidermal Necrolysis (exfoliative dermatitis)</td>
</tr>
<tr>
<td></td>
<td>Erythromelalgia</td>
</tr>
<tr>
<td></td>
<td>Photosensitivity allergic reaction</td>
</tr>
<tr>
<td></td>
<td>Palpable purpura</td>
</tr>
<tr>
<td></td>
<td>Gynaecomastia</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia</td>
</tr>
<tr>
<td></td>
<td>Myalgia</td>
</tr>
</tbody>
</table>

**Reporting Suspected Adverse Effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

### 4.9 OVERDOSE

**Symptoms**

The following symptoms are observed in cases of severe nifedipine intoxication:

Disturbances of consciousness to the point of coma, a drop in blood pressure, tachycardiac/bradycardiac heart rhythm disturbances, hyperglycaemia, metabolic acidosis, hypoxia, cardiogenic shock with pulmonary oedema.
Management of Overdose

As far as treatment is concerned, elimination of the active substance and the restoration of stable cardiovascular conditions have priority.

After oral ingestion thorough gastric lavage is indicated, if necessary in combination with irrigation of the small intestine.

Particularly in cases of intoxication with slow-release products (ADEFIN 10 and ADEFIN 20), elimination must be as complete as possible, including the small intestine, to prevent the otherwise inevitable subsequent absorption of the active substance.

Haemodialysis serves no purpose, as nifedipine is not dialysable, but plasmapheresis is advisable (high plasma protein binding, relatively low volume of distribution).

Bradycardiac heart rhythm disturbances may be treated symptomatically with β-sympathomimetics, and in life-threatening bradycardic disturbances of heart rhythm, temporary pacemaker therapy may be advisable.

Hypotension, as a result of cardiogenic shock and arterial vasodilatation, can be treated with calcium (10 to 20 mL of a 10% calcium gluconate solution administered slowly intravenously and repeated if necessary). As a result, the serum calcium can reach the upper normal range to slightly elevated levels. If the effects are inadequate, the treatment can be continued with ECG monitoring and additional β-sympathomimetics if necessary (eg. isoprenaline 0.2 mg slowly intravenously as a continuous infusion of 5 microgram/min). If an insufficient increase in blood pressure is achieved with calcium and isoprenaline, vasoconstricting sympathomimetics such as dopamine or noradrenaline (norepinephrine) are additionally administered. The dosage of these medicines is determined solely by the effect obtained.

Additional liquid or volume must be administered with caution because of the danger of overloading the heart.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of Action

Pharmacological Actions

Cardioprotective Coronary Treatment

The contractile processes of vascular smooth muscle and cardiac muscle are dependent upon calcium ions. Calcium ions enter these cells during depolarisation as slow ionic transmembrane currents. Nifedipine specifically inhibits slow inward calcium ion channels without changing serum calcium concentrations. In so doing, two distinct beneficial effects are produced which reduce anginal pain in individuals with ischaemic heart disease.

Nifedipine Improves Myocardial Oxygen Supply

Nifedipine is a potent relaxant of arterial smooth muscle. It dilates main coronary arteries and arterioles both in normal and in ischaemic myocardial regions without inducing a steal phenomenon. Nifedipine is also a potent inhibitor of coronary artery spasm. These effects increase myocardial oxygen delivery at rest and during exercise in patients with chronic stable angina, and in patients with episodes of coronary artery spasm.
Nifedipine Reduces Myocardial Work Through Afterload Reduction

As with myocardial cell contraction, regulation of the contraction of vascular smooth muscle is also dependent upon intracellular calcium ion concentration. By reducing the influx of calcium ions into vascular smooth muscle, nifedipine causes relaxation and peripheral vasodilatation. Peripheral vasodilatation reduces the impedance (afterload) against which the heart works. This unloading of the heart indirectly reduces myocardial energy consumption and oxygen requirements. Ventricular emptying is also facilitated by the reduction in impedance.

A third possible effect seen experimentally is:

Nifedipine Directly Decreases Myocardial Oxygen Consumption

During myocardial fibre depolarisation, elevation of intracellular calcium ion concentration triggers the contractile process and increases the amount of adenosine-5'-triphosphate (ATP) hydrolysed.

By inhibiting the transmembrane flux of calcium that enters myocardial cells, and hence decreasing intracellular calcium concentration, nifedipine reduces the amount of ATP hydrolysed and thereby decreases the amount of oxygen consumed by the heart. The clinical significance of this effect is as yet undecided. Unlike beta-blockers, nifedipine does not abolish responsiveness of the heart to beta-adrenergic stimulation.

Antihypertensive Effect

Nifedipine reduces the smooth muscle tone of the arterioles, thus lowering the increased peripheral resistance and consequently the blood pressure. At the beginning of the nifedipine treatment, there may be a transient reflex increase in heart rate and thus in the cardiac output. However this increase is not enough to compensate for the vasodilation.

Clinical Trials

No data available.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

After oral administration, the absorption of nifedipine from the tablet is delayed (t_{max} 1.5 to 4.2 hours) compared to a liquid capsule formulation (t_{max} 0.5 to 2.17 hours). The bioavailability of the tablet is 45 to 56%.

Distribution

Nifedipine is about 95% bound to plasma protein (albumin). Protein binding may be greatly reduced in patients with renal or hepatic impairment.

Metabolism and excretion

Nifedipine is almost completely metabolised in the body with only traces detected in the urine in an unchanged form. 70 to 80% of the dose is excreted via the kidneys in the form of highly water-soluble pharmacologically inactive metabolites. The remainder is excreted in the faeces, also in a metabolised form. The half-life of an immediate release dose form shows a mean of approximately 1.7 to 3.4 hours. Administration of the tablet results in a half-life of about 6 to 12 hours. (Continuing absorption of residual nifedipine from the gastrointestinal tract probably contributes to the prolonged half-life observed).

The pharmacological action of nifedipine persists for up to twelve hours after administration of the tablet.
In cases of impaired liver function, the elimination half-life is distinctly prolonged and the total clearance is reduced. A dose reduction may be necessary in severe cases.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity
In vitro and in vivo mutagenicity studies were negative.

Carcinogenicity
Nifedipine was administered orally to rats for two years and was not shown to be carcinogenic.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

ADEFIN tablets also contain the following inactive ingredients: – microcrystalline cellulose, polysorbate 80, magnesium stearate, hypromellose, macrogol 4000, titanium dioxide, maize starch, iron oxide red (CI 77491) and lactose monohydrate.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Tablets should be stored below 25°C. Avoid freezing. Nifedipine is highly light sensitive. The tablets should be protected from light and should be stored in the manufacturer's original container. Tablets must only be removed from the packaging immediately before use. Broken tablets should not be used.

6.5 NATURE AND CONTENTS OF CONTAINER

ADEFIN 10 : Packed in PVC/PVDC/Al blister strips of 10 tablets in boxes containing 60 tablets.

ADEFIN 20 : Packed in PVC/PVDC/Al blister strips of 10 tablets in boxes containing 60 tablets.

Some strengths, pack sizes and/or pack types may not be marketed.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.
6.7 PHYSICOCHEMICAL PROPERTIES

Chemical Structure

Chemical name: Dimethyl-1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-pyridine dicarboxylate

Structural formula:

![Structural formula of dimethyl-1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-pyridine dicarboxylate]

Molecular formula: C_{17}H_{18}N_{2}O_{6}  Molecular Weight: 346.3

Nifedipine is a yellow crystalline substance practically insoluble in water, and sparingly soluble in absolute ethanol. It is sensitive to light.

CAS Number

21829-25-4

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 (Prescription Only Medicine)

8 SPONSOR

Alphapharm Pty Limited

Level 1, 30 The Bond

30 – 34 Hickson Road

Millers Point NSW 2000

www.mylan.com.au

9 DATE OF FIRST APPROVAL

9/04/2003

10 DATE OF REVISION

03 January 2020

Summary Table of Changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Reformat of the PI to align with updated Australian form for providing product information</td>
</tr>
<tr>
<td>s</td>
<td>Schedule 1 excipients declared</td>
</tr>
<tr>
<td>4.6</td>
<td>Pregnancy category definition added for improved clarity</td>
</tr>
</tbody>
</table>

Adefin_pi\Nov19/01